Sulfur hexafluoride - Bracco
Alternative Names: BRI; E-7210; LUMASON; Lumason; LUMASON UEA; SonoVue; sulfur hexafluoride lipid-type A microspheres; Sulphur hexafluorideLatest Information Update: 09 May 2024
At a glance
- Originator Bracco
- Developer Bracco; Eisai Co Ltd
- Class Contrast media; Fluorides; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cerebrovascular disorders
- Registered Breast disorders; Cardiovascular disorders; Liver disorders; Vesicoureteral reflux
- Phase III Congenital heart defects
Most Recent Events
- 30 Apr 2024 Bracco plans a phase III trial for Heart disorders (Diagnosis) in USA (IV, Injection) (NCT06400004)
- 22 Feb 2021 The US FDA approves Sulfur hexafluoride for injectable suspension, for intravenous use or intravesical use in USA
- 18 Feb 2021 No development reported - Phase-III for Coronary artery disease (Diagnosis) in USA, Germany, United Kingdom, Belgium (IV)